Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation
Liraglutide and empagliflozin mitigate diabetes-induced cardiac damage, likely by reducing fibrosis, oxidative stress, and inflammation.
Authors
- Nazan Baksi (ORCID: https://orcid.org/0000-0002-2758-913X)
- Cemre Uçar-Ekin
- Huda Oflazoğllu-Diken
- Fırat Aşir (ORCID: https://orcid.org/0000-0002-6384-9146)
- Gül Şahika-Gökdemir
Institutions
- Dicle University (TR)
- Mardin Artuklu University (TR)
Publication Details
- Journal
- Gaceta Médica de México
- Published
- 2025-10-08
- DOI
- https://doi.org/10.24875/gmm.25000112
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Dicle Üniversitesi